IDEXX Laboratories Inc.
Last updated September 27, 2026
Organization details
- Legal name
- IDEXX Laboratories Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2835 — In Vitro & In Vivo Diagnostic Substances
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Westbrook
- Headquarters state / province
- Maine
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IDXX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000874716
- EIN
- 01-0393723
Board of directors
-
Asha Collins · DirectorSince 2023
-
Bruce L. Claflin · DirectorSince 2023
-
Daniel M. Junius · DirectorSince 2023
-
Irene Chang Britt · DirectorSince 2023
-
Jonathan Jay Mazelsky · Director · President and CEOSince 2023
-
Jonathan W. Ayers · DirectorSince 2023
-
Joseph L. Hooley · DirectorSince 2025
-
Karen Peacock · DirectorSince 2025
-
Lawrence D. Kingsley · DirectorSince 2023
-
M. Anne Szostak · DirectorSince 2023
-
Sam Samad · DirectorSince 2023
-
Sophie Vandebroek V · DirectorSince 2023
-
Stuart Essig · DirectorSince 2023
Chief executives
Jonathan Jay Mazelsky
· President and CEO
Dates unknown
Director election results
Annual meeting of May 12, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.8%
Board connections
9 of this board's directors also sit on 15 other boards.
- via Joseph L. Hooley
- via Irene Chang Britt
- via Bruce L. Claflin
- via Daniel M. Junius
- via Jonathan Jay Mazelsky
- via Karen Peacock
- via Irene Chang Britt
- via Jonathan Jay Mazelsky
- via Stuart Essig
- via Lawrence D. Kingsley
- via Stuart Essig
- via Stuart Essig
- via Lawrence D. Kingsley
- via Sophie Vandebroek V
- via Irene Chang Britt
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $37,663,343
- 36 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 4, 2026 | Lawrence D. Kingsley Director | Option exercise | +2,203 | $114.17 | $251,517 |
| Sep 4, 2026 | Lawrence D. Kingsley Director | Open-market sale | −2,203 | $532.08 | $1,172,178 |
| Aug 20, 2026 | Emerson Andrew Officer (EVP, CFO and Treasurer) | Option exercise | +265 | $178.26 | $47,239 |
| Aug 20, 2026 | Emerson Andrew Officer (EVP, CFO and Treasurer) | Shares withheld for tax | −86 | — | — |
| Jul 30, 2026 | Joseph L. Hooley Director | Grant or award | +49 | $558.80 | $27,381 |
| Jun 1, 2026 | FENNELL GEORGE Officer (Executive Vice President) | Option exercise | +639 | — | — |
| Jun 1, 2026 | FENNELL GEORGE Officer (Executive Vice President) | Shares withheld for tax | −284 | $566.79 | $160,968 |
| May 7, 2026 | Sophie Vandebroek V Director | Option exercise | +257 | — | — |
| May 7, 2026 | M. Anne Szostak Director | Option exercise | +257 | — | — |
| May 7, 2026 | Karen Peacock Director | Option exercise | +101 | — | — |
| May 7, 2026 | Lawrence D. Kingsley Director | Option exercise | +257 | — | — |
| May 7, 2026 | Daniel M. Junius Director | Option exercise | +257 | — | — |
| May 7, 2026 | Joseph L. Hooley Director | Option exercise | +158 | — | — |
| May 7, 2026 | Lawrence D. Kingsley Director | Option exercise | +82 | — | — |
| Apr 30, 2026 | Joseph L. Hooley Director | Grant or award | +43 | $560.80 | $24,114 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.